Page last updated: 2024-12-09

1-(diethylamino)-3-methyl-4-pyrido[1,2-a]benzimidazolecarbonitrile

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-(diethylamino)-3-methyl-4-pyrido[1,2-a]benzimidazolecarbonitrile is a chemical compound with the molecular formula C18H20N4. It's a complex molecule with a specific structure that makes it interesting for research purposes.

**Here's a breakdown:**

* **Structure:** The name itself hints at the structure:
* **Pyrido[1,2-a]benzimidazole:** This is a fused ring system containing a pyridine ring (six-membered ring with nitrogen) and a benzimidazole ring (fused benzene and imidazole rings).
* **1-(diethylamino):** A diethylamino group (-N(CH2CH3)2) is attached at the 1 position of the benzimidazole ring.
* **3-methyl:** A methyl group (-CH3) is attached at the 3 position of the benzimidazole ring.
* **4-carbonitrile:** A cyano group (-CN) is attached at the 4 position of the benzimidazole ring.

**Importance in Research:**

This specific compound is likely of interest due to its potential **pharmacological properties**. Here are some reasons why it could be researched:

* **Targeting Specific Biological Pathways:** The unique structure of the molecule might allow it to bind to and modulate specific proteins or enzymes involved in cellular processes. This could lead to its use as a drug or tool for studying biological pathways.
* **Antimicrobial Activity:** Some benzimidazole derivatives have shown antimicrobial activity. This compound might exhibit similar properties against bacteria, fungi, or viruses.
* **Anti-Cancer Activity:** The combination of a benzimidazole core and other functional groups might lead to anticancer activity.
* **Neuroprotective Properties:** Benzimidazole derivatives have been investigated for their potential neuroprotective effects. This compound might show activity in preventing neuronal damage.

**It's important to note:**

* **Research Stage:** The information provided is based on general knowledge about chemical structures and their potential uses. Without specific details about the research being conducted, it's impossible to know the precise reasons for studying this particular compound.
* **Safety:** Any chemical compound should be handled with care. It's crucial to follow appropriate safety procedures and protocols in research.

**To learn more about the specific research on this compound, you would need to consult research publications or databases where this compound might be listed.**

Cross-References

ID SourceID
PubMed CID679573
CHEMBL ID1488485
CHEBI ID114717

Synonyms (20)

Synonym
CBMICRO_035057
OPREA1_610176
AKOS002169839
OPREA1_351328
BIM-0034927.P001
1-diethylamino-3-methyl-benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile
smr000433717
MLS000768983
CHEBI:114717
STK842826
1-(diethylamino)-3-methylpyrido[1,2-a]benzimidazole-4-carbonitrile
HMS2797E05
CHEMBL1488485
XONJKKJNPBFWFF-UHFFFAOYSA-N
cl-2082
Q27196122
1-(diethylamino)-3-methyl-4-pyrido[1,2-a]benzimidazolecarbonitrile
1-diethylamino-3-methyl-benzo(4,5)imidazo(1,2-a)pyridine-4-carbonitrile
294850-34-3
DTXSID101323515
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyridobenzimidazoleAn organic heterotricyclic compound that is any benzimidazole ortho-fused to a pyridine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency3.98110.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency5.62345.623417.292931.6228AID485281
acid sphingomyelinaseHomo sapiens (human)Potency25.118914.125424.061339.8107AID504937
thioredoxin reductaseRattus norvegicus (Norway rat)Potency19.95260.100020.879379.4328AID588456
TDP1 proteinHomo sapiens (human)Potency20.59620.000811.382244.6684AID686978
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency12.58930.011212.4002100.0000AID1030
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency8.91250.036619.637650.1187AID1466; AID2242
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency7.30780.00419.984825.9290AID504444
importin subunit beta-1 isoform 1Homo sapiens (human)Potency39.81075.804836.130665.1308AID540263
DNA polymerase betaHomo sapiens (human)Potency89.12510.022421.010289.1251AID485314
snurportin-1Homo sapiens (human)Potency39.81075.804836.130665.1308AID540263
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency3.54810.010323.856763.0957AID2662
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency8.91253.548118.039535.4813AID1466
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Potency8.91253.548118.039535.4813AID1466
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]